BCM
ABBV icon

Beddow Capital Management’s AbbVie ABBV Stock Holding History

Beddow Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.88M Sell
25,725
-4,700
-15% -$1.07M 2.22% 18
2025
Q3 		$7.04M Sell
30,425
-1,885
-6% -$384K 2.6% 15
2025
Q2 		$6M Sell
32,310
-2,080
-6% -$387K 2.38% 17
2025
Q1 		$7.21M Sell
34,390
-570
-2% -$111K 2.7% 17
2024
Q4 		$6.21M Sell
34,960
-965
-3% -$177K 2.55% 16
2024
Q3 		$7.09M Sell
35,925
-8,571
-19% -$1.6M 2.91% 13
2024
Q2 		$7.63M Sell
44,496
-150
-0.3% -$24.8K 3.34% 8
2024
Q1 		$8.13M Sell
44,646
-9,117
-17% -$1.57M 3.56% 7
2023
Q4 		$8.33M Buy
53,763
+450
+0.8% +$65.6K 3.88% 6
2023
Q3 		$7.95M Sell
53,313
-897
-2% -$132K 3.88% 6
2023
Q2 		$7.3M Sell
54,210
-435
-0.8% -$63.8K 3.71% 8
2023
Q1 		$8.71M Sell
54,645
-1,750
-3% -$268K 4.36% 4
2022
Q4 		$9.11M Buy
56,395
+3,075
+6% +$471K 4.66% 3
2022
Q3 		$7.16M Buy
53,320
+1,875
+4% +$269K 4.33% 5
2022
Q2 		$7.88M Hold
51,445
– – 4.64% 4
2022
Q1 		$8.34M Sell
51,445
-5,600
-10% -$813K 4.4% 5
2021
Q4 		$7.72M Buy
57,045
+13,800
+32% +$1.63M 4.38% 4
2021
Q3 		$4.67M Buy
43,245
+5,661
+15% +$647K 2.79% 12
2021
Q2 		$4.23M Buy
37,584
+794
+2% +$89.4K 2.43% 13
2021
Q1 		$3.98M Buy
36,790
+810
+2% +$86.6K 2.53% 14
2020
Q4 		$3.85M Buy
35,980
+250
+0.7% +$24K 2.69% 14
2020
Q3 		$3.13M Sell
35,730
-1,045
-3% -$98.4K 2.69% 18
2020
Q2 		$3.61M Sell
36,775
-5,075
-12% -$447K 3.16% 13
2020
Q1 		$3.19M Buy
41,850
+1,675
+4% +$143K 2.94% 15
2019
Q4 		$3.56M Buy
40,175
+1,013
+3% +$84.1K 2.21% 21
2019
Q3 		$2.96M Buy
39,162
+6,520
+20% +$447K 1.87% 27
2019
Q2 		$2.37M Buy
32,642
+16,675
+104% +$1.31M 1.37% 29
2019
Q1 		$1.29M Buy
15,967
+11,695
+274% +$957K 0.71% 33
2018
Q4 		$394K Buy
+4,272
New +$376K 0.22% 36

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Beddow Capital Management's ABBV Position: Q4 2025 in Review

Beddow Capital Management reduced its AbbVie (ABBV) stake by 15% in Q4 2025, selling an estimated $1.07M and leaving 25,725 shares worth $5.88M. The position accounts for 2.22% of the portfolio, ranked #18.

Beddow Capital Management first reported a position in ABBV in Q4 2018 and has held it in 29 quarters since. The position peaked at $9.11M in Q4 2022. 4,160 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Beddow Capital Management held 25,725 shares of AbbVie worth $5.88M as of Q4 2025.
  • Beddow Capital Management sold 4,700 AbbVie shares in Q4 2025, an estimated $1.07M.
  • AbbVie made up 2.22% of Beddow Capital Management's portfolio in Q4 2025, its #18 holding.
  • Beddow Capital Management first reported a position in AbbVie in Q4 2018 and has held it in 29 quarters since.
  • Beddow Capital Management's AbbVie position peaked at $9.11M in Q4 2022.
  • 4,160 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Beddow Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.